NCT04461223 is a clinical trial of contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T) in Cardiotoxicity, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04461223?

NCT04461223 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04461223?

Interventions in NCT04461223: contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T).

What condition does NCT04461223 study?

NCT04461223 studies Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction, Doxorubicin Induced Cardiomyopathy.

Is NCT04461223 still recruiting?

NCT04461223 is currently status unknown. Last updated 8 July 2020.

Last reviewed 2020-07-08 · How we verify

NCT04461223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

Status unknown Last updated 8 July 2020

What this trial tests

trial testing contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T) in Cardiotoxicity in 55 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	55
Start date	1 December 2019
Primary completion	1 December 2021
Estimated completion	1 December 2021
Sites	1 location across China

Drugs / interventions tested

contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)

Conditions studied

Cardiotoxicity — all drugs for Cardiotoxicity →
Osteosarcoma — all drugs for Osteosarcoma →
Myocardial Injury — all drugs for Myocardial Injury →
Chemotherapy Induced Systolic Dysfunction — all drugs for Chemotherapy Induced Systolic Dysfunction →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 8 to 50, any sex, with Cardiotoxicity or Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2\* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular volume(ECV) to evaluate the respective changes before and after anthracycline chemotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Battlefield of Chemotherapy in Pediatric Cancers.
Bo L, Wang Y, Li Y, Wurpel JND, et al · · 2023 · cited 24× · PMID 37046624 · DOI 10.3390/cancers15071963
Cardiovascular Magnetic Resonance Imaging in the Early Detection of Cardiotoxicity Induced by Cancer Therapies.
Wei X, Lin L, Zhang G, Zhou X. · · 2022 · cited 4× · PMID 36010197 · DOI 10.3390/diagnostics12081846

Verify or expand the search:

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
NCT06778122 — In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors · NA · recruiting
NCT07382141 — Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age · NA · recruiting
NCT06595147 — Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study · NA · recruiting
NCT06270667 — Effects of Exercise Training in Survivors of Lymphoma · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04461223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 8 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing